Новые рекомендации EORTC по применению гранулоцитарно-колониестимулирующего фактора (Г-КСФ) для снижения риска развития фебрильной нейтропении (ФН) у взрослых пациентов с лимфомами и солидными опухолями. Алгоритм определения риска развития ФН и примене

1. Perez EA et al. Ann Oncol 2002; 13: 1225–35.
2. von Minckwitz G et al. J Clin Oncol 2005; 23: 2676–85.
3. Alba E et al. J Clin Oncol 2004; 22: 2587–93.
4. Nabholtz JM et al. J Clin Oncol 2003; 21: 968–75.
5. Biganzoli L et al. J Clin Oncol 2002; 20: 3114–21.
6. Gianni L et al. J Clin Oncol 1995; 13: 2688–99.
7. Martin M et al. Lancet Oncol 2007; 8: 219–25.
8. von Minckwitz G et al. Ann Oncol 2008; 19: 292–8.
9. National Comprehensive Cancer Network. Myeloid growth factors. <http://www.nccn.org/&gt; [по состоянию фев. 2009].
10. O’Shaughnessy J et al. J Clin Oncol 2002; 20: 2812–23.
11. Gohil S. National Cancer Research Institute Cancer Conference, 4–7 Oct., Birmingham, UK, 2009 [abstract B75].
12. Head J et al. National Cancer Research Institute Cancer Conference, 5–8 Oct., Birmingham, UK; 2008 [abstract B64].
13. Romieu G et al. Crit Rev Oncol Hematol 2007; 64: 64–72.
14. Therasse P et al. J Clin Oncol 2003; 21: 843–50.
15. Tannock IF et al. J Clin Oncol 1988; 6: 1377–87.
16. Ron IG et al. Am J Clin Oncol 2001; 24: 323–7.
17. Citron ML et al. J Clin Oncol 2003; 21: 1431–9.
18. Jassem J et al. J Clin Oncol 2001; 19: 1707–15.
19. Ardizzoni A et al. Clin Cancer Res 2003; 9: 143–50.
20. Trillet-Lenoir V et al. Eur J Cancer 1993; 29A: 319–24.
21. von Pawel J et al. J Clin Oncol 1999; 17: 658–67.
22. Lorigan P et al. J Natl Cancer Inst 2005; 97: 666–74.
23. Woll PJ et al. J Clin Oncol 1995; 13: 652–9.
24. White SC et al. Cancer 2001; 92: 601–8.
25. Ardizzoni A et al. J Clin Oncol 2002; 20: 3947–55.
26. Furuse K et al. J Clin Oncol 1998; 16: 2126–32.
27. Masutani M et al. Oncol Rep 1999; 6: 1045–50.
28. Edelman MJ et al. J Clin Oncol 2004; 22: 127–32.
29. Millward MJ et al. Ann Oncol 2003; 14: 449–54.
30. Font A et al. Cancer 1999; 85: 855–63.
31. Pirker R et al. Lancet 2009; 373: 1525–31.
32. Baldini E et al. Cancer Chemother Pharmacol 2002; 49 (Suppl. 1): S25–8.
33. Schiller JH et al. N Engl J Med 2002; 346: 92–8.
34. Fossella F et al. J Clin Oncol 2003; 21: 3016–24.
35. Wozniak AJ et al. J Clin Oncol 1998; 16: 2459–65.
36. Kelly K et al. J Clin Oncol 2001; 19: 3210–8.
37. Stathopoulos GP et al. Ann Oncol 2003; 14: 388–94.
38. Kosmidis P et al. Semin Oncol 2000; 27: 3–8.
39. Scagliotti GV et al. J Clin Oncol 2002; 20: 4285–91.
40. Cardenal F et al. J Clin Oncol 1999; 17: 12–8.
41. Sandler A et al. N Engl J Med 2006; 355: 2542–50.
42. Velasquez WS et al. J Clin Oncol 1994; 12: 1169–76.
43. Johnson PW et al. Ann Oncol 1993; 4: 63–7.
44. Ozturk MA et al. Chemotherapy 2002; 48: 252–8.
45. Martin A et al. Haematologica 2008; 93: 1829–36.
46. Osby E et al. Blood 2003; 101: 3840–8.
47. Hertzberg MS et al. Ann Oncol 2006; 17 (Suppl. 4): iv25–30.
48. Catovsky D et al. Lancet 2007; 370: 230–9.
49. Flinn IW et al. J Clin Oncol 2007; 25: 793–8.
50. Hallek M et al. Blood (ASH Annual Meeting Abstracts) 2009; 114 [abstract 535].
51. Martinelli G et al. Leuk Lymphoma 2003; 44: 801–6.
52. Dimopoulos MA et al. Leuk Lymphoma 2002; 43: 111–4.
53. Wilson WH et al. J Clin Oncol 2008; 26: 2717–24.
54. Garcia-Suarez J et al. Br J Haematol 2007; 136: 276–85.
55. Diehl V et al. N Engl J Med 2003; 348: 2386–95.
56. Federico M et al. J Clin Oncol 2009; 27: 805–11.
57. Ballova V et al. Ann Oncol 2005; 16: 124–31.
58. Silvestri F et al. Tumori 1994; 80: 453–8.
59. Verschraegen CF et al. J Clin Oncol 2000; 18: 2733–9.
60. Omura GA et al. J Clin Oncol 2003; 21: 2843–8.
61. Creemers GJ et al. J Clin Oncol 1996; 14: 3056–61.
62. Guppy AE et al. Br J Cancer 2004; 90: 810–4.
63. du Bois A et al. J Natl Cancer Inst 2003; 95: 1320–9.
64. Gordon AN et al. Gynecol Oncol 2004; 94: 533–9.
65. Papadimitriou CA et al. Gynecol Oncol 2004; 92: 152–9.
66. Vaughn DJ et al. J Clin Oncol 1998; 16: 255–60.
67. Sternberg CN et al. J Clin Oncol 2001; 19 2638–46.
68. Miller KD et al. J Clin Oncol 1997; 15: 1427–31.
69. Motzer RJ et al. J Clin Oncol 1995; 13: 2700–4.
70. Fossa SD et al. J Clin Oncol 1998; 16: 716–24.
71. Van Cutsem E et al. Br J Cancer 2004; 90: 1190–7.
72. Douillard JY, Cunningham D et al. Lancet 2000; 355: 1041–7.
73. Leonard P et al. Br J Cancer 2002; 87: 1216–20.
74. Mabro M et al. Am J Clin Oncol 2003; 26: 254–8.
75. Maindrault-Goebel F et al. Eur J Cancer 2001; 37: 1000–5.
76. Sorbye H et al. J Clin Oncol 2004; 22: 31–8.
77. Saltz LB et al. N Engl J Med 2000; 343: 905–14.
78. Bouche O et al. J Clin Oncol 2004; 22: 4319–28.
79. Van Cutsem E. J Clin Oncol 2006; 24: 4991–7.
80. Roth AD et al. J Clin Oncol 2007; 25: 3217–23.
81. Park SR et al. Br J Cancer 2006; 94: 1402–6.
82. Louvet C et al. J Clin Oncol 2002; 20: 4543–8.
83. Cunningham D et al. N Engl J Med 2008;358: 36–46.
84. Fuchs CS et al. J Clin Oncol 2003; 21: 807–14.
85. Schoemaker NE et al. Br J Cancer 2004; 91: 1434–41.
86. Shin DM et al. Cancer 2001; 91:1316–23.
87. Bui BN et al. J Clin Oncol 1995; 13: 2629–36.
88. Rose PG et al. J Clin Oncol 1999; 17: 2676–80.
89. Gobbi PG et al. J Clin Oncol 2005; 23: 9198–207.
90. Fleming GF et al. J Clin Oncol 2004; 22: 2159–66.
91. Pointreau Y et al. J Natl Cancer Inst 2009; 101: 498–506.